

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ROSTAMI *et al.*

Attorney Docket No.: **46406-0039-01-US**

(Formerly 22253-69814DIV)

Application No.: **10/743,250**

Group Art Unit: **1655**

Filed: **December 22, 2003**

Examiner: **Michele C. Flood**

Title: **USE OF BOWMAN BIRK INHIBITOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

This response is filed in response to the Restriction Requirement mailed June 30, 2006, and is accompanied by a request for a one-month extension of time, which resets the deadline for response to August 30, 2006.

The present invention involves treatment of chronic inflammation in a patient with an induced inflammatory autoimmune disease comprising administering an amount of Bowman Birk Inhibitor. The Examiner has requested an election by Applicants regarding claim 18, wherein the induced inflammatory autoimmune disease is:

- experimental autoimmune encephalomyelitis, or
- experimental autoimmune neuritis.


Applicants traverse the need to separate the two for examination purposes, since both are treated by the method of Applicants' invention. Nevertheless, Applicants first elect to prosecute experimental autoimmune encephalomyelitis as the induced disease for claim 18. No other election or restriction has been presently required.

PATENT

Should the Examiner have any questions or comments regarding Applicants' response, she is asked to contact Applicants' undersigned representative at (215) 988-3361.

Respectfully submitted,

Date: August 23, 2006



Evelyn H. McConathy
Registration No. 35,279
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Tel: (215) 988.3361
Fax: (215) 988.2757